ASCO 2018 | Trial updates in mRCC from ASCO: KEYNOTE-427, RESORT, E2810 & IMmotion151

Exciting new data for metastatic renal cell carcinoma (mRCC) was presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Here, Toni Choueiri, MD, of the Dana Farber Cancer Institute, Cambridge, MA, provides an update on the latest data in this field. Prof. Choueiri first highlights the use of pembrolizumab monotherapy in untreated mRCC in KEYNOTE-427 (NCT02853344), giving an interesting insight into the role of single agent immunotherapy in this setting. Another highlight was the results of the RESORT trial (NCT01444807) of sorafenib in mRCC following radical resection of metastases. In addition, the E2810 study from ECOG (NCT01575548), which investigated pazopanib in mRCC following surgery, is covered. Lastly, Prof. Choueiri discusses the IMmotion151 study (NCT02420821) of atezolizumab in combination with bevacizumab vs. sunitinib in untreated mRCC.